60 results
8-K
EX-99.1
ENTA
Enanta Pharmaceuticals Inc
6 May 24
Results of Operations and Financial Condition
4:05pm
. Recruitment for this cohort will continue in the Southern Hemisphere and Enanta now anticipates reporting data from this study in the second half
8-K
EX-99.1
ENTA
Enanta Pharmaceuticals Inc
7 Jun 23
Regulation FD Disclosure
7:01am
Respiratory Syncytial Virus EDP-938: Continue Phase 2 recruitment in high-risk patient populations EDP-323: Report Phase 1 data in June 2023 Human
8-K
EX-99.1
ng5g 87juac
9 May 22
Expects Topline Data From RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Virus (RSV), This Quarter
4:00pm
8-K
EX-99.1
uqco2i6ymu4fzuu
6 May 21
Results of Operations and Financial Condition
4:03pm
8-K
EX-99.1
d06rp2
8 Feb 21
Results of Operations and Financial Condition
4:05pm
DEFR14A
nmbngil7y6acorp0
28 Jan 21
Revised proxy
4:01pm